These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 35987196)
1. SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. Duan LJ; Cui XM; Zhu KL; Yao L; Wang GL; Cao WC; Ma MJ Cell Rep; 2022 Aug; 40(9):111284. PubMed ID: 35987196 [TBL] [Abstract][Full Text] [Related]
2. Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. Lu BN; Zhu KL; Cui XM; Yao L; Wang XJ; Wang GL; Duan LJ; Qian A; Ma MJ Clin Immunol; 2022 Nov; 244():109103. PubMed ID: 36049602 [TBL] [Abstract][Full Text] [Related]
3. Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. Wang B; Xu J; Wu S; Zhang Z; Zhao Z; Zhang J; Fu L; Zai X; Wang Y; Zhang G; Chen Z; Chen Y; Sun H; Song X; Zhang J; Zhu L; Hou L; Chen W Signal Transduct Target Ther; 2022 Jul; 7(1):257. PubMed ID: 35906201 [TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836 [TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico. Cervantes-Luevano K; Espino-Vazquez AN; Flores-Acosta G; Bernaldez-Sarabia J; Cabanillas-Bernal O; Gasperin-Bulbarela J; Gonzalez-Sanchez R; Comas-Garcia A; Licea-Navarro AF PLoS One; 2022; 17(6):e0269032. PubMed ID: 35749390 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ; Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298 [TBL] [Abstract][Full Text] [Related]
7. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose. Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I Front Immunol; 2023; 14():1099246. PubMed ID: 36756112 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay. Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223 [TBL] [Abstract][Full Text] [Related]
13. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5. Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903 [TBL] [Abstract][Full Text] [Related]
14. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies. Morales-Núñez JJ; Muñoz-Valle JF; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Panduro-Espinoza BV; Gallegos-Díaz de Leon JA; Munguía-Ramirez CD; Hernández-Bello J Immunol Lett; 2022 Dec; 251-252():20-28. PubMed ID: 36279685 [TBL] [Abstract][Full Text] [Related]
15. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088 [TBL] [Abstract][Full Text] [Related]
16. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR Front Immunol; 2023; 14():1055429. PubMed ID: 36845123 [TBL] [Abstract][Full Text] [Related]
17. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Tang J; Zeng C; Cox TM; Li C; Son YM; Cheon IS; Wu Y; Behl S; Taylor JJ; Chakaraborty R; Johnson AJ; Shiavo DN; Utz JP; Reisenauer JS; Midthun DE; Mullon JJ; Edell ES; Alameh MG; Borish L; Teague WG; Kaplan MH; Weissman D; Kern R; Hu H; Vassallo R; Liu SL; Sun J Sci Immunol; 2022 Oct; 7(76):eadd4853. PubMed ID: 35857583 [TBL] [Abstract][Full Text] [Related]